Rx Profiler - The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial

Despite a high initial response rate to platinum/taxane-based therapy in patients with advanced ovarian cancer, the effectiveness of treatment diminishes over time, and most patients relapse.

Ovarian cancer is an avaricious tumor that can extend throughout the entire abdominal cavity. It is one of the most difficult diseases to diagnose and the most lethal gynecologic malignancy, being the fifth leading cause of cancer death in women in the United States.

Before the 2014 FDA approval of olaparib for the treatment of recurrent ovarian cancer in patients with germline BRCA mutation and the 2016 FDA approval of bevacizumab in combination with chemotherapy for platinum-resistant ovarian cancer, the last FDA approval in ovarian cancer was in the mid-2000s.


Results 1 - 3 of 3